Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AbCellera Biologics Inc.

Get SEC filing alerts via email and in your feed for AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

About AbCellera Biologics Inc.

AbCellera Biologics Inc. specializes in discovering and developing antibody-based medicines for diseases with high unmet needs. The company integrates advanced technology, data science, and automation to accelerate antibody drug discovery from target identification to clinical candidate delivery. Serving biotechnology and pharmaceutical partners primarily in the U.S. and Europe, AbCellera’s business model combines proprietary internal programs with strategic collaborations, generating value through milestone payments, royalties, and equity stakes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from AbCellera Biologics Inc.

1
1
AbCellera Biologics Inc. AbCellera Reports 96% Revenue Growth to $8.3 Million in Q1 2026

Via official filing (AI summary) | 24 days ago | 0 comments

2
1
AbCellera Biologics Inc. AbCellera Biologics Reports 161% Revenue Growth to $75.1 Million in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
AbCellera Biologics Inc. AbCellera Biologics Reports 38% Revenue Growth in Q3 2025 Despite Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
AbCellera Biologics Inc. AbCellera Reports 133% Revenue Growth to $17.1 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
AbCellera Biologics Inc. AbCellera Reports 57% Revenue Decline and $45.6 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
AbCellera Biologics Inc. AbCellera Biologics Reports Decline in Revenue and Increase in Operating Losses for Q3 and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments